Eiger BioPharmaceuticals Inc
said on Tuesday it would discontinue a late-stage study
testing its experimental drug to treat the most severe form of
viral hepatitis, due to safety concerns.
The.
By Sabela Ojea Eiger BioPharmaceuticals said it is discontinuing the company s phase 3 study to treat peginterferon lambda in patients with chronic hepatitis delta and has ceased active.
/PRNewswire/ Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies.
Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indicationsActive discussions underway with potential partners to advance late-stage virology programsReduction in. -Today at 04:06 pm- MarketScreener